10x Genomics, Inc. TXG
62.90 USD -2.15 (-3.31%)
At closeNov 11, 2026, 8:06 AM EST
64.01 +1.11 +1.76%
Pre-market · Nov 11, 8:06 AM ET
61.42 Day range 66.16
15.12 52-week range 102.81
- YTD
- +285.65%
- 1 year
- +279.14%
News
benzinga.com 10x Genomics' Xenium Platform To Be Deployed By Fudan University Shanghai Cancer Center, Shanghai Precision Diagnostics In 24-Month Trial 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced that Fudan University Shanghai Cancer Center (FUSCC)…
prnewswire.com Shanghai Precision Diagnostics and Fudan University Shanghai Cancer Center Launch Breast Cancer Biomarker Study Using 10x Genomics' Xenium Platform Study aims to identify biomarkers that could predict how patients with breast cancer respond to neoadjuvant therapy PLEASANTON, Calif., Nov. 10, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG),…
benzinga.com JP Morgan Maintains Neutral on 10x Genomics, Lowers Price Target to $65 JP Morgan analyst Casey Woodring maintains 10x Genomics (NASDAQ:TXG) with a Neutral and lowers the price target from $70 to $65.
benzinga.com Barclays Maintains Overweight on 10x Genomics, Lowers Price Target to $70 Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:TXG) with a Overweight and lowers the price target from $110 to $70.
marketbeat.com What Torex Gold Resources (TXG) Said on Its Q3 Earnings Call Torex Gold Resources TSE: TXG reported a 37% quarter-over-quarter increase in production in the third quarter of 2026, as higher grades and improved gold recovery boosted margins and cash flow at its…
defenseworld.net 10x Genomics $TXG Stock: Chicago Partners Investment Group LLC Lowers Position Chicago Partners Investment Group LLC lowered its position in shares of 10x Genomics (NASDAQ: TXG) by 29.3% in the undefined quarter, according to the company in its most recent Form 13F filing with…- benzinga.com UBS Maintains Neutral on 10x Genomics, Lowers Price Target to $61 UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:TXG) with a Neutral and lowers the price target from $90 to $61.
- benzinga.com Citigroup Maintains Neutral on 10x Genomics, Raises Price Target to $60 Citigroup analyst Albert Hu maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $50 to $60.
zacks.com 10x Genomics Launches Sentira AI Tool to Simplify Cell Analysis TXG launches Sentira Single Cell, a Claude-powered AI tool to simplify complex data analysis, accelerate research and unlock recurring revenue potential.
zacks.com TXG Q3 Earnings Call Highlights Atera Launch and Raised Outlook 10x Genomics raises its 2026 revenue outlook on strong Atera demand and spatial consumables growth, but production constraints and margin pressure remain challenges.
marketbeat.com What 10x Genomics (TXG) Said on Its Q3 Earnings Call 10x Genomics NASDAQ: TXG raised its full-year revenue outlook after reporting modest third-quarter growth and increased its shipment target for its new Atera spatial biology platform.
benzinga.com Stifel Maintains Buy on 10x Genomics, Raises Price Target to $68 Stifel analyst Daniel Arias maintains 10x Genomics (NASDAQ:TXG) with a Buy and raises the price target from $50 to $68.
fool.com Meet the Unstoppable Vanguard ETF Beating the S&P 500 and the Dow Jones in 2026 Small-cap stocks have benefited from a range of tailwinds this year.
zacks.com Compared to Estimates, 10x Genomics (TXG) Q3 Earnings: A Look at Key Metrics The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street…
seekingalpha.com 10x Genomics, Inc. (TXG) Q3 2026 Earnings Call Transcript 10x Genomics, Inc. (TXG) Q3 2026 Earnings Call Transcript
zacks.com 10x Genomics (TXG) Reports Q3 Loss, Beats Revenue Estimates 10x Genomics (TXG) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.22 per share a year ago.
benzinga.com 10x Genomics Raises FY2026 Sales Guidance from $610.000M-$630.000M to $625.000M-$635.000M vs $619.854M Est 10x Genomics (NASDAQ:TXG) raises FY2026 sales outlook from $610.000 million-$630.000 million to $625.000 million-$635.000 million vs $619.854 million estimate.
prnewswire.com 10x Genomics Reports Third Quarter 2026 Financial Results PLEASANTON, Calif., Nov. 5, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported…
benzinga.com Vertiv, Evercore, Brinker, GE HealthCare And Other Big Stocks Moving Higher On Wednesday U.S. stocks mixed; Dow gained ~100 points. Vertiv jumped 13.3% on strong results and raised guidance; Ultralife soared 145.8% on buyout news.
benzinga.com TD Cowen Maintains Hold on 10x Genomics, Raises Price Target to $70 TD Cowen analyst Dan Brennan maintains 10x Genomics (NASDAQ:TXG) with a Hold and raises the price target from $47 to $70.- benzinga.com Morgan Stanley Maintains Equal-Weight on 10x Genomics, Raises Price Target to $70 Morgan Stanley analyst Tejas Savant maintains 10x Genomics (NASDAQ:TXG) with a Equal-Weight and raises the price target from $40 to $70.
- benzinga.com Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $100 Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:TXG) with a Buy and raises the price target from $60 to $100.
benzinga.com Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday U.S. stocks rose Friday; Humana jumped 12.3% after improved 2027 Medicare Advantage ratings and reaffirmed FY26 EPS guidance.- benzinga.com Barclays Maintains Overweight on 10x Genomics, Raises Price Target to $110 Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:TXG) with a Overweight and raises the price target from $52 to $110.
- benzinga.com 10x Genomics Partners With Fred Hutchinson Cancer Center Over Use Of Single Cell, Spatial Technologies In Both Solid Tumor And Hematologic Malignancies 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a multi-project research collaboration with Fred…
benzinga.com Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia, extending its CRISPR bet to 50 sessions.
benzinga.com 10 Stocks Rally as Rate Hike Bets Collapse on Weak September Jobs Entegris, Rocket and KLA led premarket gains after September payrolls rose just 29,000 vs. 90,000 expected, cutting bets on a Fed rate hike.- benzinga.com Leerink Partners Maintains Market Perform on 10x Genomics, Raises Price Target to $90 Leerink Partners analyst Mike Kratky maintains 10x Genomics (NASDAQ:TXG) with a Market Perform and raises the price target from $40 to $90.
- benzinga.com 10x Genomics Begins Commercial Shipments Of Its Transcriptome Analysis Tool Atera Atera is moving into the hands of researchers around the world, from those scaling existing spatial programs to researchers exploring spatial biology for the first time, across discovery,…
benzinga.com 10x Genomics Launches NVIDIA-Accelerated Sentira Spatial Analysis, Cutting Spatial Data Processing Times From Hours To Minutes Sentira Spatial Analysis leverages NVIDIA accelerated computing to cut spatial data processing times from hours to minutes, putting rapid, iterative analysis at the fingertips of every…- benzinga.com Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $80 Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $47 to $80.
benzinga.com This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Analysts initiate coverage: Buy on IonQ ($60), Jack Henry ($193) and 10X Genomics ($110); Overweight Lexicon ($8); In-Line Fortive ($60).- benzinga.com Argus Research Initiates Coverage On 10x Genomics with Buy Rating, Announces Price Target of $110 Argus Research analyst John Eade initiates coverage on 10x Genomics (NASDAQ:TXG) with a Buy rating and announces Price Target of $110.
benzinga.com Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.
benzinga.com Radiant Logistics, Waystar, Forgent Power Solutions And Other Big Stocks Moving Higher On Tuesday U.S. stocks fell, but Radiant Logistics surged 17.8% after beating Q4 estimates. Waystar, Telix and Forgent also posted strong gains.- benzinga.com 10x Genomics To Incorporate Lunit's AI-Powered Pathology Platform Into Its Oncology Biomarker Discovery Workflow Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that 10x Genomics, Inc. (Nasdaq: TXG) will incorporate Lunit's AI-powered pathology…
- benzinga.com UBS Maintains Neutral on 10x Genomics, Raises Price Target to $68 UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $20 to $68.
benzinga.com Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.- benzinga.com RBC Capital Initiates Coverage On 10x Genomics with Sector Perform Rating, Announces Price Target of $70 RBC Capital analyst Dan Leonard initiates coverage on 10x Genomics (NASDAQ:TXG) with a Sector Perform rating and announces Price Target of $70.
benzinga.com Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit 10x Genomics won a $4.8 million patent infringement lawsuit against Qiagen subsidiary Parse Biosciences, prompting plans for an injunction.- benzinga.com 10x Genomics Wins Patent Case Against Parse Biosciences As Jury Finds Willful Infringement And Awards $4.8M+ In Damages; Company To Seek Enhanced Damages, Fees And Permanent Injunction Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity challengePLEASANTON, Calif., Aug. 28, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), the life…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting strong Q4 results and positive sales guidance.- benzinga.com Stephens & Co. Maintains Overweight on 10x Genomics, Raises Price Target to $65 Stephens & Co. analyst Mason Carrico maintains 10x Genomics (NASDAQ:TXG) with a Overweight and raises the price target from $50 to $65.
- benzinga.com Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $47 Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $42 to $47.
- benzinga.com Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $60 Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:TXG) with a Buy and raises the price target from $50 to $60.
- benzinga.com Citigroup Maintains Neutral on 10x Genomics, Raises Price Target to $50 Citigroup analyst Brendan Digan maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $45 to $50.
benzinga.com Morgan Stanley Maintains Equal-Weight on 10x Genomics, Raises Price Target to $40 Morgan Stanley analyst Tejas Savant maintains 10x Genomics (NASDAQ:TXG) with a Equal-Weight and raises the price target from $37 to $40.
benzinga.com 10x Genomics Raises FY2026 Sales Guidance from $600.000M-$625.000M to $610.000M-$630.000M vs $613.851M Est 10x Genomics (NASDAQ:TXG) raises FY2026 sales outlook from $600.000 million-$625.000 million to $610.000 million-$630.000 million vs $613.851 million estimate.- benzinga.com 10x Genomics Q2 EPS $(0.14) Beats $(0.24) Estimate, Sales $151.000M Beat $146.788M Estimate 10x Genomics (NASDAQ:TXG) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.24) by 41.67 percent. This is a 150 percent decrease over earnings of $0.28…